(Q54626772)

English

Eribulin mesylate.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Eribulin mesylate (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Peter Kirkpatrick

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Timothy K Huyck

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

William Gradishar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Fil Manuguid

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

173-174

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Microtubule-binding agents: a dynamic field of cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

The halichondrins and E7389.

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Structurally simplified macrolactone analogues of halichondrin B.

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Third consensus on medical treatment of metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Treatment options for breast cancer resistant to anthracycline and taxane

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

21 January 2018

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD3389

31 March 2020

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

1 reference

https://pubmed.ncbi.nlm.nih.gov/21358731

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRD3389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21358731%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54626772&oldid=2212540798"